Novel TSC2 Small Molecule

About Quiver Bioscience

Quiver Bioscience is a private, pre-clinical stage biotech leveraging a proprietary, integrated platform of human disease models, scalable neural measurement technology, and AI to tackle the high failure rates in neurological drug development. The company has built a pipeline of wholly-owned antisense oligonucleotide (ASO) programs targeting genetically-validated pathways in chronic pain and developmental epileptic encephalopathies, and has secured strategic research collaborations with pharmaceutical partners. Positioned at the intersection of genetics, scalable biology, and computational power, Quiver aims to become a premier partner in translating target discovery into clinical candidates for CNS disorders.

Therapeutic Areas

Other Tuberous Sclerosis Complex (TSC) Drugs